Kenneth E Fasanella
Overview
Explore the profile of Kenneth E Fasanella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heaphy C, Patel S, Smith K, Wondisford A, Lynskey M, OSullivan R, et al.
Mod Pathol
. 2024 Nov;
38(3):100651.
PMID: 39522643
Molecular studies have shown alternative lengthening to telomeres (ALT) to be an important prognostic biomarker of shorter relapse-free survival (RFS) for patients with pancreatic neuroendocrine tumors (PanNETs) and other neoplasms....
2.
Aijazi M, Fasanella K, McGrath K, Smith L, Singhi A, Brand R
Pancreas
. 2024 Mar;
53(4):e350-e356.
PMID: 38518061
Background: The International Cancer of the Pancreas Screening Consortium recommended annual imaging for individuals at increased risk for developing a pancreatic ductal adenocarcinoma (PDAC) who did not have concerning pancreatic...
3.
Hackeng W, Brosens L, Kim J, OSullivan R, Sung Y, Liu T, et al.
Gut
. 2021 Apr;
71(5):961-973.
PMID: 33849943
Objective: Recent studies have found aristaless-related homeobox gene (ARX)/pancreatic and duodenal homeobox 1 (PDX1), alpha-thalassemia/mental retardation X-linked (ATRX)/death domain-associated protein (DAXX) and alternative lengthening of telomeres (ALT) to be promising...
4.
Das R, McGrath K, Seiser N, Smith K, Uttam S, Brand R, et al.
Clin Gastroenterol Hepatol
. 2020 Dec;
20(4):886-897.
PMID: 33278573
Background & Aims: The assessment of therapeutic response after neoadjuvant treatment and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) has been an ongoing challenge. Several limitations have been encountered when employing...
5.
AlMasri S, Zenati M, Dasyam A, Singhi A, Lee K, Bartlett D, et al.
Ann Surg
. 2020 Nov;
275(6):e789-e795.
PMID: 33201115
Objective: To evaluate the significance of UDD in IPMNs. Background: The uncinate process of the pancreas has an independent ductal drainage system. International consensus guidelines of IPMNs still consider it...
6.
Tokuyama M, Geisler D, Deitrick C, Fasanella K, Chennat J, McGrath K, et al.
Histopathology
. 2020 May;
77(3):481-491.
PMID: 32431062
Aims: Abnormal p53 protein expression detected by immunohistochemistry (IHC) in Barrett's oesophagus (BO) is reported to be a prognostic biomarker for progression to high-grade dysplasia (HGD) or oesophageal adenocarcinoma (OAC)....
7.
Singhi A, Wood L, Parks E, Torbenson M, Felsenstein M, Hruban R, et al.
Gastroenterology
. 2019 Nov;
158(3):573-582.e2.
PMID: 31678302
Background & Aims: Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct contain epithelial cells with numerous, large mitochondria and are cystic precursors to pancreatic ductal adenocarcinoma (PDAC)...
8.
Singhi A, Nikiforova M, Chennat J, Papachristou G, Khalid A, Rabinovitz M, et al.
Gut
. 2019 Apr;
69(1):52-61.
PMID: 30971436
Objective: Despite improvements in imaging, serum CA19-9 and pathological evaluation, differentiating between benign and malignant bile duct strictures remains a diagnostic conundrum. Recent developments in next-generation sequencing (NGS) have opened...
9.
Ooka K, Fasanella K, Hashash J
Gastroenterology
. 2019 Jan;
156(4):e10-e11.
PMID: 30612996
No abstract available.
10.
Chao D, Shah N, Zeh 3rd H, Singhi A, Bahary N, McGrath K, et al.
Gastroenterol Res Pract
. 2018 Jul;
2018:2380596.
PMID: 29967636
Background: Adolescent obesity is a national epidemic that recently has been shown to increase risk for pancreatic adenocarcinoma (PC) and is associated with an earlier age of PC onset. We...